Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.68 |
| ▸ | ALPI | P09923 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | XIAP | P98170 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenclonine SCHEMBL26382 | 1.00 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Fenclonine SCHEMBL26383 | 1.00 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Fenclonine SCHEMBL3140768 | 1.00 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Fenclonine SCHEMBL6357978 | 0.98 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| Fenclonine SCHEMBL16825893 | 0.98 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| Fenclonine SCHEMBL988270 | 0.98 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| Fenclonine SCHEMBL28422788 | 0.94 | SLC7A5 (0.79) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL30722994 | 0.94 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL20714933 | 0.94 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| Fenclonine SCHEMBL8497239 | 0.94 | SLC7A5 (0.79) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 897 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | claimed |
| EP-4696700-A1 | LONG-ACTING K-OPIOID RECEPTOR AGONIST | Chengdu Aoda Biotechnology Co., Ltd (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4696699-A1 | ? OPIOID RECEPTOR AGONIST AND USE THEREOF | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4665374-A1 | METHODS OF PREVENTING AND/OR TREATING SIDE EFFECTS ASSOCIATED WITH ANTI-CANCER AGENTS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH ANTI-GDF-15 ANTIBODIES | Endevica Bio, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245292-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245288-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2004098629-A1 | GnRH CONJUGATES COMPRISING A PHOTOSENSITIZER FOR PHOTODYNAMIC THERAPY | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-11-18 | — | — | WO | claimed |
| WO-2003006048-A1 | COMBINATION OF CHIPS (CHEMOTAXIS INHIBITING PROTEIN FROM STAPHYLOCOCCUS AUREUS)-BASED COMPOUNDS | JARI PHARMACEUTICALS B.V. (NL) | 2003-01-23 | — | — | WO | claimed |
| US-RE37710-E1 | IMAGING TUMOR | IMMUNOMEDICS, INC. | 2002-05-21 | — | — | US | claimed |
| US-5753206-A | Radiometal-binding analogues of luteinizing hormone releasing hormone | IMMUNOMEDICS, INC. (US) | 1998-05-19 | — | — | US | claimed |
| EP-0836618-A1 | RADIOMETAL-BINDING ANALOGUES OF LEUTENIZING HORMONE RELEASING HORMONE | Immunomedics, Inc. (US) | 1998-04-22 | — | — | EP | claimed |
| WO-1996040756-A1 | RADIOMETAL-BINDING ANALOGUES OF LEUTENIZING HORMONE RELEASING HORMONE | IMMUNOMEDICS, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0593491-B1 | LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST PEPTIDES | DEGHENGHI ROMANO (CH) | 1996-10-23 | — | — | EP | claimed |
| EP-0593491-A1 | LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST PEPTIDES. | DEGHENGHI ROMANO (CH) | 1994-04-27 | — | — | EP | claimed |
| WO-1992019651-A1 | LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST PEPTIDES | DEGHENGHI ROMANO (CH) | 1992-11-12 | — | — | WO | claimed |
| US-4693993-A | ANTIINFLAMMATORY | VAVREK, RAYMOND J. | 1987-09-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | SLC7A5 161/4885PTGS1 2336/4885ALPI 455/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | SLC7A5 670/4885PTGS1 1358/4885ALPI 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.